These studies providing mechanistic insights into the up-regulation of the PRLR by EGF hormone and its receptor kinase indicate the relevance of their joint participation in tumor progression and resistance to adjuvant therapies and further the basis for the treatment of refractory states in ERα+ breast cancers. The gene discussed is ESR1; the disease is breast cancer.